News


Kymab and Heptares enter strategic collaboration to discover, develop and commercialise novel antibody therapeutics

Kymab Limited, a leading human monoclonal antibody biopharmaceutical company and Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology.